SI2875013T1 - INDOL CARBONITRILS AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR - Google Patents
INDOL CARBONITRILS AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR Download PDFInfo
- Publication number
- SI2875013T1 SI2875013T1 SI201330945T SI201330945T SI2875013T1 SI 2875013 T1 SI2875013 T1 SI 2875013T1 SI 201330945 T SI201330945 T SI 201330945T SI 201330945 T SI201330945 T SI 201330945T SI 2875013 T1 SI2875013 T1 SI 2875013T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- compound according
- muscular atrophy
- chronic
- repair
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 102000001307 androgen receptors Human genes 0.000 claims abstract 2
- 108010080146 androgen receptors Proteins 0.000 claims abstract 2
- 201000000585 muscular atrophy Diseases 0.000 claims 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010020100 Hip fracture Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SKDVMPZQJMZEAC-SECBINFHSA-N 1-[(2r)-1-methylsulfonylpropan-2-yl]-4-(trifluoromethyl)indole-5-carbonitrile Chemical compound N#CC1=CC=C2N([C@@H](CS(C)(=O)=O)C)C=CC2=C1C(F)(F)F SKDVMPZQJMZEAC-SECBINFHSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672455P | 2012-07-17 | 2012-07-17 | |
| US201361748874P | 2013-01-04 | 2013-01-04 | |
| EP13758975.0A EP2875013B1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
| PCT/IB2013/001530 WO2014013309A1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2875013T1 true SI2875013T1 (en) | 2018-03-30 |
Family
ID=49117887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201330945T SI2875013T1 (en) | 2012-07-17 | 2013-07-15 | INDOL CARBONITRILS AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR |
Country Status (39)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
| PE20150371A1 (es) | 2012-07-17 | 2015-03-27 | Glaxosmithkline Ip No 2 Ltd | Indolcarbonitrilos como moduladores selectivos del receptor de androgeno |
| JP6556738B2 (ja) | 2014-01-21 | 2019-08-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | （ｒ）−１−（１−（メチルスルホニル）プロパン−２−イル）−４−（トリフルオロメチル）インドリン−５−カルボニトリルの結晶形 |
| KR101994922B1 (ko) * | 2014-10-16 | 2019-07-01 | 지티엑스, 인코포레이티드 | Sarm을 이용하는 비뇨기 장애의 치료 방법 |
| CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
| CN110437125B (zh) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | 一种Tezacaftor中间体II的制备方法 |
| US20220306609A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| CN115010574B (zh) * | 2022-06-06 | 2024-01-05 | 爱斯特（成都）生物制药股份有限公司 | 1-溴-2-氯-4-氟-2碘苯的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299347A (zh) | 1998-02-25 | 2001-06-13 | 遗传研究所有限公司 | 磷脂酶抑制剂 |
| KR100415791B1 (ko) * | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| WO2003099777A1 (en) | 2002-05-24 | 2003-12-04 | Bayer Cropscience Ag | Process for the preparation of thioalkylamine derivatives |
| CN1960973A (zh) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物 |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| EP1771413B1 (en) | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
| US7427682B2 (en) | 2004-05-03 | 2008-09-23 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
| CA2564952A1 (en) | 2004-05-03 | 2005-11-24 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (sarms) |
| NZ551292A (en) * | 2004-06-01 | 2009-11-27 | Hoffmann La Roche | 3-Amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| DK1913000T3 (da) * | 2005-07-29 | 2012-03-12 | Pfizer Prod Inc | Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| CN101426778A (zh) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | 作为组胺-3拮抗剂的n-经取代-氮杂环基胺 |
| AU2007227681A1 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| EP2079466B1 (en) * | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
| CN102131812B (zh) * | 2008-08-20 | 2014-04-09 | 硕腾有限责任公司 | 吡咯并[2，3-d]嘧啶化合物 |
| WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| AU2010308028A1 (en) * | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
| CA2782720A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| CN103384661B (zh) | 2011-01-20 | 2016-08-10 | 默沙东公司 | 盐皮质激素受体拮抗剂 |
| RU2618673C2 (ru) * | 2011-12-21 | 2017-05-10 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Производные пирролопиримидина, полезные в качестве ингибиторов jak-киназы |
| PE20150371A1 (es) * | 2012-07-17 | 2015-03-27 | Glaxosmithkline Ip No 2 Ltd | Indolcarbonitrilos como moduladores selectivos del receptor de androgeno |
| JP6556738B2 (ja) * | 2014-01-21 | 2019-08-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | （ｒ）−１−（１−（メチルスルホニル）プロパン−２−イル）−４−（トリフルオロメチル）インドリン−５−カルボニトリルの結晶形 |
-
2013
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/es active IP Right Grant
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/zh active Active
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/lt unknown
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/hu unknown
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/pt active IP Right Grant
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/me unknown
- 2013-07-15 EA EA201492237A patent/EA026371B8/ru not_active IP Right Cessation
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 RS RS20180119A patent/RS56810B1/sr unknown
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 SM SM20180115T patent/SMT201800115T1/it unknown
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 AR ARP130102513A patent/AR091770A1/es active IP Right Grant
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 PL PL13758975T patent/PL2875013T3/pl unknown
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/es active Active
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 PT PT137589750T patent/PT2875013T/pt unknown
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 UY UY0001034911A patent/UY34911A/es not_active Application Discontinuation
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/ja active Active
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/ar active
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/ko active Active
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 MX MX2015000825A patent/MX349943B/es active IP Right Grant
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 HR HRP20180061TT patent/HRP20180061T1/hr unknown
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 TW TW102125297A patent/TWI574946B/zh active
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en not_active Ceased
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/es unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/es unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/es unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104A1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/es unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/el unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2875013T1 (en) | INDOL CARBONITRILS AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EA201790568A1 (ru) | Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| JP2015522603A5 (Direct) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| GEP20257788B (en) | Methods and compositions for treating sleep apnea | |
| EA201100133A1 (ru) | Антагонисты рецепторов простагландина d | |
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| MX2009001534A (es) | Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva. | |
| JP2016041733A5 (Direct) | ||
| EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| DK2148670T3 (da) | Titrering af tapentadol | |
| DK1765349T3 (da) | Opioider til behandling af kronisk obstruktiv lungesygdom | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| JP2017105859A5 (Direct) | ||
| MX2009013205A (es) | Derivados de pirazoloquinolina urea terapeuticos. |